vall d'hebron

The Catalan research centre has unveiled a new 625-square-metre space where the Academic Research Organisation (ARO) will be based. The ARO will provide support for clinical trials developed throughout the world regarding quality control, methodological, regulatory, statistical and management aspects. Furthermore, the new space has 7 medical boxes, nursery support and a lab to process the samples, which will provide an integral service for clinical trials. The new facilities will be able to host between 750 and 1,100 patients per year and work on 350 trials. It cost €1.2 million, which came from public funds.

This is a real stride for the cancer research. The effects of a protein called condensing on colorectal cancer have been found out by a team of Molecular Biology and Biochemistry experts, at the Research Centre for Nanomedicine (CIBBIN-Nanomedicine) at the Vall d'Hebon Research Institute. The researchers have discovered that condensin helps the tumor cells to divide rapidly, so its inhibition leads to the death of tumour cells. The results of this research were published in the 'Journal of Biology and Chemistry', and they constitute a real hope for the fight against colorectal cancer.

Staff members from Catalonia’s main hospitals, including Sant Pau, Vall d’Hebron, Clínic, Parc Taulí and Germans Trias i Pujol, carried out several protests on Wednesday. Some of these protests had already started a few days ago and might last a few days longer, such as spending the night in the hospital lobby. They are demonstrating to criticise the budget cuts affecting health centres and to defend the public healthcare system. Some of these hospitals are recognised at an international level for their top quality clinical and scientific research work.

The Barcelona-based Vall d’Hebron Research Institute (VHIR) has identified two proteins that block the metastasis of rhabdomyosarcoma, a type of cancer that represents 8% of this sort of illness in children. These two proteins are related to cellular proliferation and growth as well as having the capacity to migrate to other organs. The study opens the door to the development of new treatments targeting these two proteins. The study was funded by the foundation of the Catalan Public TV Broadcaster and it has been published in the British Journal of Cancer (BJC).

For the first time in the world, Barcelona’s Vall d’Hebron Hospital removes two tumours through the body’s natural holes without the support of laparoscopy. This technique allows the patient to recover much quicker, since there are no external wounds to cicatrise. They have successfully removed a colon tumour and a stomach one, from two different patients who had recovered without complications.

The New York-based centre is considered the world’s best hospital in the fight against cancer. Dr. Baselga will direct a team of 834 doctors attending more than 123,000 patients per year. The Catalan doctor is currently Chief of the Division of Hematology/Oncology at Massachusetts General Hospital (MGH), Associate Director of the MGH Cancer Center, and Scientific Director of the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. Furthermore, Dr. Baselga holds a Chair of Medicine at the Universitat Autònoma de Barcelona (UAB). The Catalan doctor will combine his new job in New York, which will start on January 1st, with his position in Barcelona’s centre.

For the first time in the world, a foetus having the spina bifida congenital disorder went through a new intra-uterus surgery technique. A medical team from Barcelona’s Vall d’Hebron Hospital operated on the foetus in its 24th week by placing a biological fabric on the spinal cord, in order to protect it from amniotic liquid and to ease the gap’s closing. The baby is now five months old and doctors are confident she may walk without any problems.

"This could mean a breakthrough in the fight against cancer," said the head of the study Juan Angel Recio from Barcelona-based Vall d’Hebron Research Institute.

The new drug, called ‘Eribulin’, improves the survival rate of patients with a metastasis from breast cancer by 20%. The drug has been developed by a multinational team lead by staff from Barcelona’s Vall d’Hebron Hospital. The study has been published in the reference medical journal ‘The Lancet’.

Scientists from the Vall d'Hebron Institute for Research in Barcelona find that patients are more likely to develop respiratory difficulties when there is a failure in the activation of immune response genes.

4 months after the surgery, the patient is said to be "happy" with his new image. The Vall d?Hebron Hospital of Barcelona performed the operation. It is the 1st full face transplant, after 13 partial face transplants in the world.